<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Previously undiagnosed myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Previously undiagnosed myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Previously undiagnosed myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason Tarkin, MBBS, PhD, MRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald S Bloomfield, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H50655634"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Incidental findings are common in medicine and often lead to diagnostic and management dilemmas. This topic discusses one such patient group: asymptomatic individuals who are found to have a previously undiagnosed myocardial infarction (MI). </p><p class="headingAnchor" id="H1583177985"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>According to the Fourth Universal Definition of MI, criteria for silent/unrecognized MI include any one of the following criteria [<a href="#rid1">1</a>] (see  <a class="medical medical_review" href="/z/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Prior MI'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Pathological Q waves with or without symptoms in the absence of non-ischemic causes</p><p class="bulletIndent1"><span class="glyph">●</span>Imaging evidence of loss of viable myocardium in a pattern consistent with ischemic etiology</p><p class="bulletIndent1"><span class="glyph">●</span>Pathoanatomical findings of a prior MI</p><p></p><p>The term "previously undiagnosed" MI is used synonymously to describe either a "silent" MI, when no symptoms are recalled by the patient, or an "unrecognized" MI in a patient who, despite experiencing atypical symptoms related to their MI, did not seek medical attention at that time as they did not recognize their symptoms to be harmful. The literature has used both of these terms interchangeably over the last few decades. In either case, owing to a lack of classic symptoms, there is an invariable delay in diagnosis and treatment of these patients, and often the MI will go undiscovered for months or even years. </p><p>Patients who present with symptoms or late complications of a "missed" MI (a term that refers to an individual with chest pain that is inappropriately managed as a noncardiac cause and subsequently found to have sustained an acute MI within the next 24 to 48 hours) represent a different patient cohort [<a href="#rid2">2-4</a>]. The approach to these patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction"</a> and  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H2065986561"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>There are two principal clinical scenarios in which a previously undiagnosed MI might be suspected. This diagnosis is most commonly associated with the finding of an abnormal electrocardiogram (ECG) with significant abnormalities, usually pathological Q waves, discovered incidentally during a routine health checkup [<a href="#rid5">5,6</a>]. Persistent ST-segment and T wave ECG abnormalities, though less specific for MI than Q waves, can also be signs of prior MI in asymptomatic patients. In this scenario, ECG patterns suggestive of prior MI are often identified by ECG machines with automated interpretation (eg, "cannot exclude anterior MI"). </p><p>Previously undiagnosed MIs might also be detected by cardiac imaging. For example, this diagnosis could be inferred by the presence of regional wall motion abnormalities observed incidentally on an echocardiogram (obtained for a different reason) [<a href="#rid7">7</a>]. Similarly, sub-endocardial or transmural myocardial scarring detected by cardiac magnetic resonance imaging with late gadolinium enhancement  (<a class="graphic graphic_diagnosticimage graphicRef111923" href="/z/d/graphic/111923.html" rel="external">image 1</a>) [<a href="#rid8">8</a>], intramyocardial fatty scars on cardiac computed tomography scans, or an irreversible perfusion defect found on myocardial perfusion scanning [<a href="#rid9">9,10</a>] are additional findings that can be unexpected. An initial noninvasive imaging strategy is recommended for many patients with suspected stable coronary disease [<a href="#rid11">11</a>]. We predict that in the future, as more tests are performed, incidental detection of previously undiagnosed MIs by cardiac imaging is likely to become an increasingly common occurrence.</p><p class="headingAnchor" id="H1902868591"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>It is not uncommon for prior undiagnosed MIs to be found in otherwise asymptomatic patients in community or outpatient settings. Observational studies conducted primarily in White males between 1976 and 1998 estimated between 20 to 40 percent of MIs are unrecognized [<a href="#rid12">12-15</a>]. For example, in a Framingham analysis (1990), unrecognized MI represented 30 percent of all infarctions [<a href="#rid12">12</a>]. Studies of the Reykjavik cohort demonstrated that 35 percent of MIs in males and 33 percent of MIs in females escaped clinical detection, with a prevalence of &gt;5 percent in individuals aged 75 to 79 years [<a href="#rid16">16,17</a>]. Similarly, in the Honolulu Heart study, one-third of all Q wave MIs were clinically unrecognized [<a href="#rid14">14</a>]. In the Bronx Aging Study, which evaluated individuals at least 75 years of age, 43.5 percent of MIs were clinically unrecognized [<a href="#rid18">18</a>].</p><p>More contemporary population-based cohort studies, performed after 2000, confirm that up to one-fifth of MIs defined by electrocardiograph (ECG) Q wave criteria are clinically undetected. In the Cardiovascular Health study (2000), 901 of the 5888 (15.3 percent) participants, who were all ≥65 years of age, had ECG evidence of prior MI at baseline, of which 201 (22.3 percent) were classified as clinically unrecognized MI [<a href="#rid19">19</a>]. In the ICELAND MI study (2012), the prevalence of unrecognized MI by ECG criteria in a community dwelling cohort of older individuals in Iceland was 5 percent [<a href="#rid20">20</a>]. Isolated minor Q waves were also present in 377 of 6551 (5.8 percent) individuals in the Multi-Ethnic Study of Atherosclerosis (MESA) study (2013) [<a href="#rid21">21</a>]. Data from the Atherosclerosis Risk in Communities (ARIC) study (2002), where serial ECGs were reviewed before and after incident MIs diagnosed by hospital records in patients aged 45 to 65 years, showed that 20 percent of incident MIs were unrecognized, with African Americans having a slightly higher incidence than White Americans (23 versus 19 percent) [<a href="#rid22">22</a>].</p><p>In a case control study of 5869 patients with verified sudden cardiac death, 42.4 percent of patients without a clinical history of coronary artery disease had silent MI at autopsy, and 67 percent of these individuals had abnormal premorbid ECGs [<a href="#rid23">23</a>]. However, many MI patients do not develop Q waves or indeed any other persistent ECG abnormalities. In fact, up to 20 percent of patients with nonrecurrent MI have been noted to have normal ECGs four years after their event [<a href="#rid24">24</a>]. Thus, a highly sensitive imaging modality such as cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) has the potential to identify more undiagnosed MIs than screening with ECG. When compared with CMR, the overall sensitivity of Q wave ECG criteria for MI is roughly 50 percent, despite its high specificity of 85 to 95 percent [<a href="#rid25">25,26</a>]. Of 936 individuals studied in ICELAND-MI, 157 (17 percent) had unrecognized MI diagnosed by CMR, which was significantly higher than the 46 (5 percent) detected by ECG [<a href="#rid20">20</a>]. Similarly, the prevalence of CMR-detected unrecognized MI was 20 percent in another study of 259 selected 70-year-olds in Sweden [<a href="#rid27">27</a>]. Myocardial scarring was also reported in 146 of 1840 (8 percent) individuals in the MESA cohort who underwent CMR with LGE at year 10 of follow-up, of which 114 (78 percent) were undetectable by ECG or clinical adjudication [<a href="#rid28">28</a>]. In contrast to the high prevalence of CMR-detected MI in unselected older adult populations, perhaps unsurprisingly, undiagnosed MI was found to be very low (0.2 percent) in a study of 5000 middle-age patients without prior cardiovascular disease and with low- to intermediate-risk scores who underwent CMR imaging [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3178836588"><span class="h1">CLINICAL RISK PREDICTORS</span><span class="headingEndMark"> — </span>Several clinical risk factors have been associated with an increased likelihood of undiagnosed MI. Older age [<a href="#rid30">30</a>], female gender [<a href="#rid31">31,32</a>], hypertension [<a href="#rid33">33</a>], and diabetes mellitus [<a href="#rid34">34</a>] are all associated with atypical MI symptoms, providing at least theoretical rationale that presence of these clinical factors might help predict which patients are more likely to have undiagnosed MI. Whether or not significant clinical benefit is gained from routine ECG screening for unrecognized MI in asymptomatic patients with clinical cardiovascular risk factors remains to be determined. </p><p>While it remains unclear why some patients with MI do not experience overt chest pain, it is likely that silent myocardial ischemia results from several mechanisms in these individuals, including autonomic dysfunction, cardiovascular autonomic neuropathy, abnormalities in afferent pain gating mechanisms, and central factors leading to altered pain perception [<a href="#rid35">35-39</a>]. (See  <a class="medical medical_review" href="/z/d/html/1488.html" rel="external">"Silent myocardial ischemia: Epidemiology, diagnosis, treatment, and prognosis"</a>.)</p><p class="headingAnchor" id="H3744661002"><span class="h2">Age</span><span class="headingEndMark"> — </span>Undiagnosed MI is more common in older patients. In the Reykjavik study discussed above, the prevalence of unrecognized MI increased steeply after age 60 years; it was 0.5 percent at age 50 years and exceeded 5 percent at age 75 years [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1431697993"><span class="h2">Sex</span><span class="headingEndMark"> — </span>Sex-based differences have also been reported in some studies. Data from ARIC and ICELAND-MI [<a href="#rid40">40,41</a>], published in 2016, as well as the Rotterdam study [<a href="#rid42">42</a>] showed that undetected MI was more common in males than females, a finding that contrasts earlier reports where either no sex difference was observed [<a href="#rid22">22</a>] or increased prevalence was seen in females [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H1282689552"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Although hypertension has been identified as an independent risk factor for undiagnosed MI in some studies [<a href="#rid13">13,44</a>], this relationship has not been consistently observed [<a href="#rid14">14,16</a>]. In a study that directly compared risk factors in older adult patients with unrecognized MI versus recognized MI, age, female gender, and hypertension were all significant predictors of unrecognized MI (odd ratios 1.18, 1.45, and 1.06, respectively, p&lt;0.05 for all) [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H355780327"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>The prevalence of MI has also been shown to be increased in patients with chronic kidney disease and microalbuminuria compared with those without [<a href="#rid45">45</a>]. In the <a class="drug drug_general" data-topicid="8640" href="/z/d/drug information/8640.html" rel="external">Irbesartan</a> Diabetic Nephropathy Trial, 14 percent of all first nonfatal MIs were clinically unrecognized in patients with diabetes mellitus, hypertension, and nephropathy during a mean follow-up of 2.5 years [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1739600277"><span class="h2">Diabetes</span><span class="headingEndMark"> — </span>Diabetes mellitus is an important clinical risk factor for undiagnosed MI [<a href="#rid47">47</a>]. The prevalence of unrecognized Q wave MI at baseline in the <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> Evaluated For Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study was 1.9 percent [<a href="#rid48">48</a>] and, similarly, in the <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">Fenofibrate</a> Intervention and Event Lowering in Diabetes (FIELD) study, the prevalence was 2.7 percent [<a href="#rid49">49</a>]. A slightly higher prevalence of silent MIs detected by ECG criteria were observed in patients with diabetes in the Fremantle cohort from Australia at 4 percent, which amounted to 44 percent of all Q wave MIs in this study [<a href="#rid50">50</a>]. In the United Kingdom Prospective Diabetes Study, 17.5 percent of patients with diabetes had Q waves identified on their ECG at baseline, rising to 30 percent at 12 years [<a href="#rid51">51</a>]; however, the ECG criteria used in this study might not have been specific enough to exclude a high proportion of false positives [<a href="#rid52">52</a>]. Undiagnosed MI also appears to be more common in patients with impaired fasting glucose compared with those with normal fasting glucose [<a href="#rid53">53</a>], and diabetes mellitus has been identified as an independent predictor of silent MI in patients referred for myocardial perfusion imaging [<a href="#rid9">9</a>]. However, among patients with type 2 diabetes, no clinical factor significantly increased the odds ratio for silent versus clinically recognized MI in the FIELD study that included analysis of 31,390 serial ECGs from 9795 patients aged 50 to 75 years over an average five-year follow-up [<a href="#rid49">49</a>]. In a retrospective analysis of 732 patients with diabetes mellitus and no known history of coronary heart disease from the DISCO cohort who underwent CT coronary artery calcification (CAC) scanning, 83 (21 percent) had intramyocardial fat suggestive of previous MI on their CT scan, including 28 (11.6 percent) patients with CAC score of 0 and 55 (37.6 percent) with CAC ≥300 [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3219079270"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Data from large observational cohort studies show that patients with asymptomatic Q wave MI diagnosed by ECG criteria have a similar [<a href="#rid19">19,40</a>], or worse [<a href="#rid14">14,18</a>],<sup> </sup>long-term prognosis compared with those with clinically apparent MI in whom prompt treatment is initiated. The risk of incident cardiovascular events, including MI and cardiovascular death, for isolated minor Q waves in asymptomatic individuals was observed to be greater than in those without isolated Q waves in the MESA cohort (16.1 versus 10.4 per 1000-person year; p = 0.01) [<a href="#rid21">21</a>]. However, after adjusting for demographics, cardiovascular risk factors, socioeconomic status, and other electrocardiographic (ECG) abnormalities, the presence of minor isolated Q waves was strongly associated with incident cardiovascular events in Hispanic individuals (hazard ratio [HR] 2.62) but not in White or Black individuals. Evidence from the ARIC study showed that silent MI also increases the risk of heart failure by 35 percent compared with patients without MI [<a href="#rid54">54</a>]. Silent MI diagnosed by Q wave ECG criteria was an independent predictor of subsequent ischemic stroke in the Cardiovascular Health Study [<a href="#rid55">55</a>] and of sudden cardiac death in a meta-analysis of the ARIC and Cardiovascular Health Study cohorts [<a href="#rid56">56</a>].</p><p>Asymptomatic patients with cardiac magnetic resonance (CMR)-detected MI also have significantly increased risk for future cardiovascular disease (CVD) events compared with individuals without CMR-evidence of prior MI. In a study of 248 unselected 70-year-olds followed up for a mean 11 years, CMR-detected unrecognized MI was associated with &gt;twofold risk of major adverse cardiac events (MACE) compared with those with no MI [<a href="#rid57">57</a>]. In another study, diabetic patients with prior MI detected by CMR had an even higher fourfold increase in MACE over a period of 17 months compared with those without [<a href="#rid58">58</a>]. Clinically unrecognized MI detected by CMR (but not ECG criteria) was also associated with increased mortality in ICELAND-MI after adjustment for covariates (HR 1.45; 8 percent increased absolute risk) [<a href="#rid20">20</a>]. Further evidence demonstrating the prognostic implications of CMR-detected undiagnosed MI is provided by two prospective longitudinal studies of patients with suspected stable coronary artery disease who lacked Q waves on their ECGs [<a href="#rid59">59,60</a>]. Moreover, the Strong Heart Study showed that echocardiographic segmental left ventricular wall motion abnormalities indicative of previous MI in adults without overt cardiovascular disease were associated with a 2.5-fold increased risk of cardiovascular events or death, independent of established risk factors [<a href="#rid61">61</a>]. </p><p>The relatively high number of CVD events may be attributable to multiple factors, including a lower rate of the use of proven preventive therapy, such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and statins (see  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>). In a post-hoc analysis of the MESA study, it was observed that both non-zero coronary artery calcification (CAC) score and CAC ≥100 were more common in patients with evidence of silent MI on ECG compared with those without, linking incidental ECG abnormalities with a prognostic imaging biomarker [<a href="#rid62">62</a>]. Moreover, the high prevalence of comorbid conditions observed in patients with silent MIs (including diabetes mellitus, chronic kidney disease, and systemic hypertension), as well as the fact that these patients are less likely to undergo percutaneous coronary artery stenting within the recommended 24- to 72-hour window following their event, are additional factors that potentially contribute the increased risk observed in this patient cohort.</p><p class="headingAnchor" id="H4202103878"><span class="h1">DIFFICULTIES WITH ELECTROCARDIOGRAM DIAGNOSIS</span><span class="headingEndMark"> — </span>The Fourth Universal definition of MI [<a href="#rid1">1</a>] defines pathological Q waves by the following criteria: </p><p class="bulletIndent1"><span class="glyph">●</span>Any Q wave in leads V2-V3 &gt;0.02 seconds or QS complex in leads V2-V3</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Q wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF or V4-V6 in any two leads of a contiguous lead grouping</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>R wave &gt;0.04 seconds in V1-V2 and R/S &gt;1 with a concordant positive T wave in absence of conduction defect</p><p></p><p>Q waves are more likely to be diagnostic of a prior MI when an inverted T wave is also present in the same lead. However, it is important to recognize that the finding of pathological Q waves, when combined with giant negative T waves, could indicate presence of an underlying inherited cardiomyopathy (eg, hypertrophic cardiomyopathy) rather than a true MI (see  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a>). In patients with hypertrophic cardiomyopathy, abnormal depolarization due to septal hypertrophy often results in Q waves in the inferior and lateral leads. A pseudoinfarct electrocardiographic (ECG) pattern with QS waves in two consecutive leads is also observed in approximately 50 percent of individuals with cardiac amyloidosis. Overall, the Q and QS wave patterns have moderate specificity (75 percent) and sensitivity (58 percent) for MI when compared with myocardial scintigraphy [<a href="#rid63">63</a>]. While the ECG criteria for MI listed above are more sensitive and have greater negative predictive value than previously recommended criteria, this comes at the cost of lower specificity and positive predictive value [<a href="#rid64">64</a>].</p><p>There are a number of situations in which a Q wave is present on an ECG but does not represent true MI. A QS complex in lead V1 is normal. A narrow (&lt;0.03 seconds) and shallow (&lt;25 percent of R wave) Q wave in lead III is normal if the frontal QRS axis is between -30 and 0 degrees. Similarly, a Q wave in aVL may be normal if the frontal QRS axis is between 60 and 90 degrees. Septal Q waves in leads I, aVL, aVF, or V4-V6 that are &lt;0.03 seconds and &lt;25 percent of the R wave amplitude in these leads are nonpathologic. </p><p>Although the presence of right bundle branch block (RBBB) is not usually thought to interfere with the ECG diagnosis of Q wave MI in clinical practice, several reports have shown associations between RBBB and both false-negative and false-positive ECG diagnoses of Q wave MI [<a href="#rid65">65</a>]. Therefore, the finding of a new Q wave in an asymptomatic individual with a RBBB pattern on ECG warrants further corroboration to establish the diagnosis of transmural infarction. Similarly, left anterior fascicular block (LAFB) poses a diagnostic challenge when Q waves are present in leads V2 or V3, which occurs in 5 percent of patients with LAFB [<a href="#rid66">66</a>]. </p><p>Other situations that can mimic the ECG diagnosis of prior MI include respiratory Q waves in lead III arising from chest wall motion [<a href="#rid67">67</a>] and electrolyte abnormalities. Incorrect lead placement, left ventricular hypertrophy, and presence of left bundle branch block may also lead to a false positive ECG.</p><p>Finally, the ECG may represent MI, but there are multiple causes of MI that are not caused by obstructive coronary artery disease. Examples include nonischemic cardiomyopathies or myocarditis associated with scarring or coronary artery dissection. </p><p class="headingAnchor" id="H301668514"><span class="h1">FURTHER DIAGNOSTIC TESTING</span><span class="headingEndMark"> — </span>The challenge for the general clinician is to determine which patients with abnormal or borderline ECG criteria for previously undiagnosed MI require further cardiac testing to confirm MI. Referral to a specialist may be useful in situations where the diagnosis remains in doubt. (See <a class="local">'Referral to a specialist'</a> below.)</p><p>To confirm MI in an asymptomatic patient with Q waves on ECG, the ECG should first be repeated to ensure that lead malposition or respiratory changes are not the cause  (<a class="graphic graphic_algorithm graphicRef113841" href="/z/d/graphic/113841.html" rel="external">algorithm 1</a>). The next step is to assess the cardiovascular risk profile of the patient and to inquire about the presence of cardiac symptoms in order to determine the clinical likelihood of an MI. From a practical point of view, in asymptomatic patients, clinical risk stratification tools designed to guide primary prevention treatment strategies, such as the "ASCVD" score that provides sex- and race-specific 10-year cardiovascular disease risk estimates based on pooled cohort data from studies performed in the United States [<a href="#rid68">68</a>] or the "QRISK3" [<a href="#rid69">69</a>] score based on general practice registry data from the United Kingdom, may be applied here. (See  <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">"Cardiovascular disease risk assessment for primary prevention: Risk calculators"</a>.)</p><p>For most patients in whom a repeat ECG has confirmed the presence of worrisome abnormalities, we consider troponin testing when a recent event is suspected because of symptoms recalled by the patient or evolving changes on serial ECGs. </p><p>In most patients, we obtain additional diagnostic (and prognostic) information using stress or anatomical imaging (eg, coronary computed tomography angiography [CCTA]) (see  <a class="medical medical_review" href="/z/d/html/5308.html" rel="external">"Cardiac imaging with computed tomography and magnetic resonance in the adult", section on 'Cardiac CT'</a>). For those patients at very low risk of a prior infarction based on the ECG, we may evaluate regional left ventricular function with echocardiography only. </p><p>The ischemic cascade paradigm indicates that myocardial ischemia predictably progresses through a series of steps to produce clinical disease by causing coronary flow maldistribution, hypoperfusion, diastolic dysfunction, systolic dysfunction, stress-induced ECG changes, and, ultimately, angina. Thus, a range of noninvasive imaging techniques that detect cardiac perfusion, wall thickness, and function can be used, with or without stress testing, to confirm presence of atherosclerotic coronary artery disease or infarcted myocardium in patients with suspected MI based on the ECG. </p><p>In an otherwise asymptomatic patient, echocardiography, myocardial perfusion scintigraphy, and cardiac magnetic resonance imaging (CMR) are functional tests that can be used to detect prior infarction. CCTA is another useful test with very high sensitivity to exclude the presence of obstructive atherosclerotic coronary artery disease in appropriately selected patients, particularly when the ECG diagnosis is uncertain. Unlike functional tests, CCTA directly interrogates coronary atherosclerotic plaque and can inform about the anatomical distribution and burden of disease, stenosis severity, and plaque morphological characteristics associated with adverse prognosis. CCTA is the recommended first-line imaging test for many patients with stable chest pain and ECG abnormalities. Aside from diagnosing coronary disease, evidence of prior MI on CCTA includes myocardial thinning, regional wall motion abnormalities on retrospectively gated cine imaging, and focal intramyocardial fat deposition (defined by low attenuation) due to healed MI. </p><p>Beyond standard transthoracic echocardiography, choice of first-line noninvasive testing for suspected coronary disease will be guided by local expertise and availability and should be directed by specialist input.</p><p>The strength of echocardiography is the ability to assess cardiac structure and function without the need for potentially nephrotoxic contrast or exposure to ionizing radiation. Regional myocardial function can be assessed with conventional two-dimensional imaging, three-dimensional imaging, tissue Doppler, or myocardial strain imaging using speckle tracking. A normal, good quality echocardiogram without wall motion abnormality and normal myocardial strain pattern in a patient with asymptomatic Q waves on ECG decreases the likelihood that there is a true prior MI. Use of echo contrast can also enhance detection of potentially scarred myocardium. Stress testing (with echocardiography, radionuclide imaging, or magnetic resonance imaging [MRI]) can also be used in such instances when the clinical suspicion remains high or the patient is otherwise at increased risk for having coronary artery disease. Myocardial global longitudinal strain, for example, increases during exercise stress echocardiography in healthy adults without MI [<a href="#rid70">70</a>] and is attenuated in those with coronary artery disease [<a href="#rid71">71</a>]. </p><p>Radionuclide imaging can detect myocardial viability and inducible perfusion abnormalities. Radionuclide imaging can also identify myocardial motion, thickening, and ejection fraction; however, this technique has poor spatial resolution compared with echocardiography or MRI. </p><p>CMR offers high spatial resolution, the option for stress perfusion imaging, and is particularly useful for tissue characterization. Unlike echocardiography and radionuclide imaging, CMR can identify the pattern and severity of myocardial fibrosis throughout the myocardium and across myocardial layers (see  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'CMR after myocardial infarction'</a>). The last point is especially relevant to patients presenting with asymptomatic Q waves on ECG because MRI can distinguish between subendocardial patterns of fibrosis versus other patterns of fibrosis (eg, mid-wall scarring due to myocarditis) that can mimic prior myocardial infarction. While CMR has advantages, echocardiography may be more accessible to many clinicians.</p><p class="headingAnchor" id="H45189567"><span class="h1">MANAGEMENT AFTER CONFIRMATION OF THE DIAGNOSIS</span><span class="headingEndMark"> — </span>Long-term management of patients with previously undiagnosed MI due to obstructive coronary artery disease should not differ from that of clinically recognized MI, as lack of overt clinical symptoms at the time of presentation has no relation to the severity of underlying atherosclerotic coronary artery disease or indeed long-term prognosis. However, none of the clinical trials of MI were specifically designed to test efficacy of drug intervention in asymptomatic patients in whom the diagnosis was incidental. </p><p>Young females with MI who present without symptoms are a particularly high-risk group [<a href="#rid72">72,73</a>], in whom prompt treatment is critical [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/1467.html" rel="external">"Clinical features and diagnosis of coronary heart disease in women"</a> and  <a class="medical medical_review" href="/z/d/html/50.html" rel="external">"Coronary artery disease and myocardial infarction in young people"</a> and  <a class="medical medical_review" href="/z/d/html/1520.html" rel="external">"Management of coronary heart disease in women"</a>.)</p><p>The diagnosis and prognosis should be discussed with all patients.</p><p class="headingAnchor" id="H3768634341"><span class="h2">Secondary prevention</span><span class="headingEndMark"> — </span>Secondary preventive therapies should be started in all patients with MI. Secondary prevention begins with risk factor modification, including lifestyle intervention (eg, healthy eating, weight reduction, regular exercise, and smoking cessation), and treatment to correct high blood pressure, reduce low density lipoprotein cholesterol, and improve glycemic control in diabetic patients. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>All patients with confirmed MI, regardless of whether or not they experienced symptoms at the time of presentation, should be prescribed long-term <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> as the first-line antiplatelet agent to reduce the risk of death and nonfatal MI, provided there is no contraindication. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease", section on 'Summary and recommendations'</a>.)</p><p>Unless contraindicated, dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a PY2<sub>12</sub> receptor inhibitor (eg, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>) is recommended for 12 months after MI. While the timing of the event is often unknown in patients with previously undetected MI, a practical approach would be to consider a treatment strategy including dual antiplatelet therapy for one year in patients with recent symptoms or who are found to have an elevated troponin at the time of diagnosis. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Summary and recommendations'</a>.)</p><p>High intensity statin therapy is recommended for all patients with MI, unless contraindicated, as this has been shown to improve mortality. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/100.html" rel="external">"Low-density lipoprotein-cholesterol (LDL-C) lowering after an acute coronary syndrome", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease", section on 'Summary and recommendations'</a>.)</p><p>Long-term treatment with beta blockers (eg, <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>) is recommended for all patients with MI. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy", section on 'Long-term therapy'</a>.)</p><p>Angiotensin converting enzyme (ACE) inhibitors are recommended for patients after MI with left ventricular systolic impairment ≤40 percent, heart failure (HF), hypertension, or diabetes. Moreover, there is also some prognostic evidence to support the use of ACE inhibitors in patients with stable atherosclerotic disease without HF or left ventricular systolic dysfunction [<a href="#rid75">75</a>].<strong> </strong>An angiotensin receptor blocker may be used when there is a contraindication or intolerance to ACE inhibitor. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>.)</p><p>Mineralocorticoid receptor antagonists (eg, <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>) are also indicated in patients with left ventricular systolic impairment ≤40 percent and either HF or diabetes after an MI, who are receiving therapeutic doses of ACE inhibitor and beta blocker, and who lack significant renal dysfunction or hyperkalaemia [<a href="#rid76">76,77</a>]. </p><p>Angiotensin receptor-neprilysin inhibitor (as a replacement for ACE inhibitor) and SGLT2 inhibitors are recommended in patients with symptomatic HF and reduced ejection fraction to reduce the risk of HF hospitalization and death. (See  <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p>Pharmacologic management of patients with prior MI who develop symptoms of stable angina is discussed elsewhere [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a>.) </p><p>Patients with Q waves on their ECG who are determined to not have MI nevertheless have an increased risk of future cardiovascular events compared with the general population and should therefore be considered for aggressive primary prevention. However, there are no randomized trials or comparative effectiveness research studies to inform long-term management for patients with Q waves on ECG that do not represent true MI. </p><p class="headingAnchor" id="H1941646685"><span class="h2">Prognostic evaluation</span><span class="headingEndMark"> — </span>Similar to patients with a new diagnosis of stable ischemic heart disease, we refer the patient for stress testing or noninvasive anatomical imaging with computed tomographic coronary angiography to screen for severe coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care", section on 'Determining disease severity'</a>.) </p><p>For patients with stress evidence of severe disease or prognostically significant anatomical disease, we proceed with optimal medical therapy and diagnostic coronary angiography and revascularization if indicated. (See  <a class="medical medical_review" href="/z/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care", section on 'Identifying patients for angiography and revascularization'</a>.)</p><p class="headingAnchor" id="H3890744806"><span class="h2">Routine follow-up</span><span class="headingEndMark"> — </span>Patients with confirmed undiagnosed MI who are asymptomatic, have normal cardiac function, who lack prognostically significant coronary disease (ie, left main stem or multi-vessel disease), and do not have functional myocardial ischemia can be followed by their primary care clinician without the need for ongoing specialist care. This routine follow-up should include regular monitoring of modifiable cardiovascular risk factors to ensure good blood pressure, lipid, and glycemic control. Provided there are no concerns, we suggest these checks are performed on a six monthly to yearly basis.</p><p class="headingAnchor" id="H3630339777"><span class="h1">REFERRAL TO A SPECIALIST</span><span class="headingEndMark"> — </span>Patients with prior MI who develop symptoms of stable angina, heart failure, arrhythmias, or other MI complications should be referred for specialist opinion.</p><p>As such, patients with previously undiagnosed MI should be educated about the risks of their condition and made aware of symptoms (typical and atypical) that might indicate the need for urgent medical attention. Similarly, asymptomatic patients who are identified on noninvasive testing to have impaired left ventricular systolic dysfunction, significant myocardial ischemia, or anatomically prognostic coronary artery disease should also be referred to specialist input. In this context, invasive coronary angiography might be indicated to define the anatomy, even in asymptomatic patients, to guide management decisions, including the need for coronary revascularization. Specialist input might also be required in cases where, after initial assessment, alternative diagnoses (eg, cardiomyopathy, myocarditis, or cardiac amyloidosis) are suspected. </p><p>Even if asymptomatic, patients with pathological Q waves and giant negative T waves should be referred to a specialist center for evaluation of a possible inherited cardiomyopathy if a diagnosis of old MI has been excluded.</p><p class="headingAnchor" id="H3749600488"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115939.html" rel="external">"Society guideline links: Chronic coronary syndrome"</a>.)</p><p class="headingAnchor" id="H92291949"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>– The term "previously undiagnosed" myocardial infarction (MI) is used synonymously to describe either a "silent" MI, when no symptoms are recalled by the patient, or an "unrecognized" MI in a patient who, despite experiencing atypical symptoms related to their MI, did not seek medical attention at that time. (See <a class="local">'Definitions'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– There are two principal clinical scenarios in which a previously undiagnosed MI might be suspected: an abnormal electrocardiogram (ECG) with significant abnormalities, usually pathological Q waves, discovered incidentally during a routine health checkup, and an abnormal noninvasive cardiac imaging test obtained for another reason.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– Patients with previously undiagnosed MI have a similar or worse<sup> </sup>long-term prognosis compared with those with clinically apparent MI in whom prompt treatment is initiated. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification </strong>– Patients with previously undiagnosed MI should undergo risk stratification using available risk score and should have additional testing with stress or anatomical imaging. (See <a class="local">'Further diagnostic testing'</a> above and <a class="local">'Prognostic evaluation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term medical management</strong> – In patients with previously undiagnosed MI due to obstructive coronary artery disease, long-term medical management is similar to that of clinically recognized MI and should include long-term <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, beta blocker, and statin. (See <a class="local">'Management after confirmation of the diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018; 72:2231.</a></li><li><a class="nounderline abstract_t">Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163.</a></li><li><a class="nounderline abstract_t">McCarthy BD, Beshansky JR, D'Agostino RB, Selker HP. Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993; 22:579.</a></li><li><a class="nounderline abstract_t">Lee TH, Rouan GW, Weisberg MC, et al. Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room. Am J Cardiol 1987; 60:219.</a></li><li><a class="nounderline abstract_t">Savage RM, Wagner GS, Ideker RE, et al. Correlation of postmortem anatomic findings with electrocardiographic changes in patients with myocardial infarction: retrospective study of patients with typical anterior and posterior infarcts. Circulation 1977; 55:279.</a></li><li><a class="nounderline abstract_t">Horan LG, Flowers NC, Johnson JC. Significance of the diagnostic Q wave of myocardial infarction. Circulation 1971; 43:428.</a></li><li><a class="nounderline abstract_t">Ammar KA, Samee S, Makwana R, et al. Echocardiographic characteristics of electrocardiographically unrecognized myocardial infarctions in a community population. Am J Cardiol 2005; 96:1069.</a></li><li><a class="nounderline abstract_t">Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113:2733.</a></li><li><a class="nounderline abstract_t">Arenja N, Mueller C, Ehl NF, et al. Prevalence, extent, and independent predictors of silent myocardial infarction. Am J Med 2013; 126:515.</a></li><li><a class="nounderline abstract_t">Boccalini S, Teulade M, Paquet E, et al. Silent myocardial infarction fatty scars detected by coronary calcium score CT scan in diabetic patients without history of coronary heart disease. Eur Radiol 2023.</a></li><li><a class="nounderline abstract_t">Fordyce CB, Douglas PS. Optimal non-invasive imaging test selection for the diagnosis of ischaemic heart disease. Heart 2016; 102:555.</a></li><li><a class="nounderline abstract_t">Kannel WB, Cupples LA, Gagnon DR. Incidence, precursors and prognosis of unrecognized myocardial infarction. Adv Cardiol 1990; 37:202.</a></li><li><a class="nounderline abstract_t">Medalie JH, Goldbourt U. Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors. Ann Intern Med 1976; 84:526.</a></li><li><a class="nounderline abstract_t">Yano K, MacLean CJ. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 1989; 149:1528.</a></li><li><a class="nounderline abstract_t">Grimm RH Jr, Tillinghast S, Daniels K, et al. Unrecognized myocardial infarction: experience in the Multiple Risk Factor Intervention Trial (MRFIT). Circulation 1987; 75:II6.</a></li><li><a class="nounderline abstract_t">Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995; 122:96.</a></li><li><a class="nounderline abstract_t">Jónsdóttir LS, Sigfusson N, Sigvaldason H, Thorgeirsson G. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. Eur Heart J 1998; 19:1011.</a></li><li><a class="nounderline abstract_t">Nadelmann J, Frishman WH, Ooi WL, et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 1990; 66:533.</a></li><li><a class="nounderline abstract_t">Sheifer SE, Gersh BJ, Yanez ND 3rd, et al. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000; 35:119.</a></li><li><a class="nounderline abstract_t">Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 2012; 308:890.</a></li><li><a class="nounderline abstract_t">Li Y, Dawood FZ, Chen H, et al. Minor isolated Q waves and cardiovascular events in the MESA study. Am J Med 2013; 126:450.e9.</a></li><li><a class="nounderline abstract_t">Boland LL, Folsom AR, Sorlie PD, et al. Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study). Am J Cardiol 2002; 90:927.</a></li><li><a class="nounderline abstract_t">Vähätalo JH, Huikuri HV, Holmström LTA, et al. Association of Silent Myocardial Infarction and Sudden Cardiac Death. JAMA Cardiol 2019; 4:796.</a></li><li><a class="nounderline abstract_t">Cox CJ. Return to normal of the electrocardiogram after myocardial infarction. Lancet 1967; 1:1194.</a></li><li><a class="nounderline abstract_t">Asch FM, Shah S, Rattin C, et al. Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study. Am Heart J 2006; 152:742.</a></li><li><a class="nounderline abstract_t">Krittayaphong R, Maneesai A, Chaithiraphan V, et al. Comparison of diagnostic and prognostic value of different electrocardiographic criteria to delayed-enhancement magnetic resonance imaging for healed myocardial infarction. Am J Cardiol 2009; 103:464.</a></li><li><a class="nounderline abstract_t">Barbier CE, Bjerner T, Johansson L, et al. Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group. J Am Coll Cardiol 2006; 48:765.</a></li><li><a class="nounderline abstract_t">Turkbey EB, Nacif MS, Guo M, et al. Prevalence and Correlates of Myocardial Scar in a US Cohort. JAMA 2015; 314:1945.</a></li><li><a class="nounderline abstract_t">Weir-McCall JR, Fitzgerald K, Papagiorcopulo CJ, et al. Prevalence of unrecognized myocardial infarction in a low-intermediate risk asymptomatic cohort and its relation to systemic atherosclerosis. Eur Heart J Cardiovasc Imaging 2017; 18:657.</a></li><li><a class="nounderline abstract_t">Tresch DD. Management of the older patient with acute myocardial infarction: difference in clinical presentations between older and younger patients. J Am Geriatr Soc 1998; 46:1157.</a></li><li><a class="nounderline abstract_t">Arslanian-Engoren C, Patel A, Fang J, et al. Symptoms of men and women presenting with acute coronary syndromes. Am J Cardiol 2006; 98:1177.</a></li><li><a class="nounderline abstract_t">Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? Am Heart J 2004; 148:27.</a></li><li><a class="nounderline abstract_t">Falcone C, Auguadro C, Sconocchia R, Angoli L. Susceptibility to pain in hypertensive and normotensive patients with coronary artery disease: response to dental pulp stimulation. Hypertension 1997; 30:1279.</a></li><li><a class="nounderline abstract_t">Umachandran V, Ranjadayalan K, Ambepityia G, et al. The perception of angina in diabetes: relation to somatic pain threshold and autonomic function. Am Heart J 1991; 121:1649.</a></li><li><a class="nounderline abstract_t">Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med 2001; 135:801.</a></li><li><a class="nounderline abstract_t">Øhrn AM, Nielsen CS, Schirmer H, et al. Pain Tolerance in Persons With Recognized and Unrecognized Myocardial Infarction: A Population-Based, Cross-Sectional Study. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">Droste C, Roskamm H. Experimental pain measurement in patients with asymptomatic myocardial ischemia. J Am Coll Cardiol 1983; 1:940.</a></li><li><a class="nounderline abstract_t">Rosen SD, Paulesu E, Nihoyannopoulos P, et al. Silent ischemia as a central problem: regional brain activation compared in silent and painful myocardial ischemia. Ann Intern Med 1996; 124:939.</a></li><li><a class="nounderline abstract_t">Faerman I, Faccio E, Milei J, et al. Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes 1977; 26:1147.</a></li><li><a class="nounderline abstract_t">Zhang ZM, Rautaharju PM, Prineas RJ, et al. Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2016; 133:2141.</a></li><li><a class="nounderline abstract_t">McAreavey D, Vidal JS, Aspelund T, et al. Midlife Cardiovascular Risk Factors and Late-Life Unrecognized and Recognized Myocardial Infarction Detect by Cardiac Magnetic Resonance: ICELAND-MI, the AGES-Reykjavik Study. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">de Torbal A, Boersma E, Kors JA, et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J 2006; 27:729.</a></li><li><a class="nounderline abstract_t">Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984; 311:1144.</a></li><li><a class="nounderline abstract_t">Rosenman RH, Friedman M, Jenkins CD, et al. Clinically unrecognized myocardial infarction in the Western Collaborative Group Study. Am J Cardiol 1967; 19:776.</a></li><li><a class="nounderline abstract_t">Rizk DV, Gutierrez O, Levitan EB, et al. Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. Nephrol Dial Transplant 2012; 27:3482.</a></li><li><a class="nounderline abstract_t">Aguilar D, Goldhaber SZ, Gans DJ, et al. Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. Am J Cardiol 2004; 94:337.</a></li><li><a class="nounderline abstract_t">Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis 2011; 104:178.</a></li><li><a class="nounderline abstract_t">MacDonald MR, Petrie MC, Home PD, et al. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care 2011; 34:1394.</a></li><li><a class="nounderline abstract_t">Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010; 31:92.</a></li><li><a class="nounderline abstract_t">Davis TME, Fortun P, Mulder J, et al. Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia 2004; 47:395.</a></li><li><a class="nounderline abstract_t">Davis TM, Coleman RL, Holman RR, UKPDS Group. Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation 2013; 127:980.</a></li><li><a class="nounderline abstract_t">Scirica BM. Prevalence, incidence, and implications of silent myocardial infarctions in patients with diabetes mellitus. Circulation 2013; 127:965.</a></li><li><a class="nounderline abstract_t">Stacey RB, Leaverton PE, Schocken DD, et al. Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis. Am Heart J 2015; 170:923.</a></li><li><a class="nounderline abstract_t">Qureshi WT, Zhang ZM, Chang PP, et al. Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study. J Am Coll Cardiol 2018; 71:1.</a></li><li><a class="nounderline abstract_t">Merkler AE, Bartz TM, Kamel H, et al. Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study. Neurology 2021; 97:e436.</a></li><li><a class="nounderline abstract_t">Cheng YJ, Jia YH, Yao FJ, et al. Association Between Silent Myocardial Infarction and Long-Term Risk of Sudden Cardiac Death. J Am Heart Assoc 2021; 10:e017044.</a></li><li><a class="nounderline abstract_t">Barbier CE, Themudo R, Bjerner T, et al. Long-term prognosis of unrecognized myocardial infarction detected with cardiovascular magnetic resonance in an elderly population. J Cardiovasc Magn Reson 2016; 18:43.</a></li><li><a class="nounderline abstract_t">Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008; 118:1011.</a></li><li><a class="nounderline abstract_t">Nordenskjöld AM, Hammar P, Ahlström H, et al. Unrecognized Myocardial Infarction Assessed by Cardiac Magnetic Resonance Imaging--Prognostic Implications. PLoS One 2016; 11:e0148803.</a></li><li><a class="nounderline abstract_t">Kim HW, Klem I, Shah DJ, et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med 2009; 6:e1000057.</a></li><li><a class="nounderline abstract_t">Cicala S, de Simone G, Roman MJ, et al. Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study. Circulation 2007; 116:143.</a></li><li><a class="nounderline abstract_t">Kazibwe R, Singleton MJ, German CA, et al. Association of silent myocardial infarction on electrocardiogram and coronary artery calcium: The Multi-Ethnic Study of Atherosclerosis. Ann Noninvasive Electrocardiol 2023; 28:e13081.</a></li><li><a class="nounderline abstract_t">Sandler LL, Pinnow EE, Lindsay J. The accuracy of electrocardiographic Q waves for the detection of prior myocardial infarction as assessed by a novel standard of reference. Clin Cardiol 2004; 27:97.</a></li><li><a class="nounderline abstract_t">Jensen JK, Øvrehus K, Møldrup M, et al. Redefinition of the Q wave -- is there a clinical problem? Am J Cardiol 2006; 97:974.</a></li><li><a class="nounderline abstract_t">Gussak I, Wright RS, Bjerregaard P, et al. False-negative and false-positive ECG diagnoses of Q wave myocardial infarction in the presence of right bundle-branch block. Cardiology 2000; 94:165.</a></li><li><a class="nounderline abstract_t">Shettigar UR, Pannuri A, Barbier GH, Appunn DO. Significance of anterior Q waves in left anterior fascicular block--a clinical and noninvasive assessment. Clin Cardiol 2002; 25:19.</a></li><li><a class="nounderline abstract_t">Bodenheimer MM, Banka VS, Helfant RH. Determination of lead III Q waves significance. Utility of deep inspiration. Arch Intern Med 1977; 137:437.</a></li><li><a class="nounderline abstract_t">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357:j2099.</a></li><li><a class="nounderline abstract_t">Larsen AH, Clemmensen TS, Wiggers H, Poulsen SH. Left Ventricular Myocardial Contractile Reserve during Exercise Stress in Healthy Adults: A Two-Dimensional Speckle-Tracking Echocardiographic Study. J Am Soc Echocardiogr 2018; 31:1116.</a></li><li><a class="nounderline abstract_t">Ejlersen JA, Poulsen SH, Mortensen J, May O. Diagnostic value of layer-specific global longitudinal strain during adenosine stress in patients suspected of coronary artery disease. Int J Cardiovasc Imaging 2017; 33:473.</a></li><li><a class="nounderline abstract_t">Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA 2012; 307:813.</a></li><li><a class="nounderline abstract_t">Champney KP, Frederick PD, Bueno H, et al. The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarction. Heart 2009; 95:895.</a></li><li><a class="nounderline abstract_t">Mehta LS, Beckie TM, DeVon HA, et al. Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association. Circulation 2016; 133:916.</a></li><li><a class="nounderline abstract_t">Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581.</a></li><li><a class="nounderline abstract_t">Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.</a></li><li><a class="nounderline abstract_t">Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.</a></li><li><a class="nounderline abstract_t">Tarkin JM, Kaski JC. Pharmacological treatment of chronic stable angina pectoris. Clin Med (Lond) 2013; 13:63.</a></li></ol></div><div id="topicVersionRevision">Topic 110218 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153967" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fourth Universal Definition of Myocardial Infarction (2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770981" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Missed diagnoses of acute cardiac ischemia in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442548" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3618483" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/832343" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Correlation of postmortem anatomic findings with electrocardiographic changes in patients with myocardial infarction: retrospective study of patients with typical anterior and posterior infarcts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5544988" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Significance of the diagnostic Q wave of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214440" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Echocardiographic characteristics of electrocardiographically unrecognized myocardial infarctions in a community population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754804" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23597799" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence, extent, and independent predictors of silent myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37530810" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Silent myocardial infarction fatty scars detected by coronary calcium score CT scan in diabetic patients without history of coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826100" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Optimal non-invasive imaging test selection for the diagnosis of ischaemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220449" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence, precursors and prognosis of unrecognized myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/132128" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Unrecognized myocardial infarction: five-year incidence, mortality, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2742427" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3815790" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Unrecognized myocardial infarction: experience in the Multiple Risk Factor Intervention Trial (MRFIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993002" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9717035" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2392974" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636269" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948699" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582938" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Minor isolated Q waves and cardiovascular events in the MESA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12398956" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31290935" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of Silent Myocardial Infarction and Sudden Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4165135" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Return to normal of the electrocardiogram after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996851" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: a cardiac magnetic resonance imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19195503" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of diagnostic and prognostic value of different electrocardiographic criteria to delayed-enhancement magnetic resonance imaging for healed myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904547" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26547466" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and Correlates of Myocardial Scar in a US Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27550660" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence of unrecognized myocardial infarction in a low-intermediate risk asymptomatic cohort and its relation to systemic atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736113" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of the older patient with acute myocardial infarction: difference in clinical presentations between older and younger patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17056322" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Symptoms of men and women presenting with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215788" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Symptoms in acute coronary syndromes: does sex make a difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9369288" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Susceptibility to pain in hypertensive and normotensive patients with coronary artery disease: response to dental pulp stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035379" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The perception of angina in diabetes: relation to somatic pain threshold and autonomic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11694105" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Unrecognized myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28003255" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pain Tolerance in Persons With Recognized and Unrecognized Myocardial Infarction: A Population-Based, Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6826984" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Experimental pain measurement in patients with asymptomatic myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624061" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Silent ischemia as a central problem: regional brain activation compared in silent and painful myocardial ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/590638" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27185168" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26873683" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Midlife Cardiovascular Risk Factors and Late-Life Unrecognized and Recognized Myocardial Infarction Detect by Cardiac Magnetic Resonance: ICELAND-MI, the AGES-Reykjavik Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16478749" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6482932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6026145" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinically unrecognized myocardial infarction in the Western Collaborative Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167594" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15276098" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497307" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21562320" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797259" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14963648" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362315" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23459575" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prevalence, incidence, and implications of silent myocardial infarctions in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542500" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prediabetes and the association with unrecognized myocardial infarction in the multi-ethnic study of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29301615" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Silent Myocardial Infarction and Long-Term Risk of Heart Failure: The ARIC Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34031202" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Silent Myocardial Infarction and Subsequent Ischemic Stroke in the Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33372536" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association Between Silent Myocardial Infarction and Long-Term Risk of Sudden Cardiac Death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27430315" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-term prognosis of unrecognized myocardial infarction detected with cardiovascular magnetic resonance in an elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725488" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885831" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Unrecognized Myocardial Infarction Assessed by Cardiac Magnetic Resonance Imaging--Prognostic Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381280" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576870" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37551134" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Association of silent myocardial infarction on electrocardiogram and coronary artery calcium: The Multi-Ethnic Study of Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14979630" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The accuracy of electrocardiographic Q waves for the detection of prior myocardial infarction as assessed by a novel standard of reference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563898" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Redefinition of the Q wave -- is there a clinical problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279322" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : False-negative and false-positive ECG diagnoses of Q wave myocardial infarction in the presence of right bundle-branch block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11808834" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Significance of anterior Q waves in left anterior fascicular block--a clinical and noninvasive assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/849082" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Determination of lead III Q waves significance. Utility of deep inspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222018" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28536104" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30098870" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Left Ventricular Myocardial Contractile Reserve during Exercise Stress in Healthy Adults: A Two-Dimensional Speckle-Tracking Echocardiographic Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27878406" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnostic value of layer-specific global longitudinal strain during adenosine stress in patients suspected of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357832" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147625" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26811316" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905022" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21073363" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Eplerenone in patients with systolic heart failure and mild symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471456" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23472498" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pharmacological treatment of chronic stable angina pectoris.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
